Arbutus Biopharma Corp

NASDAQ: ABUS
$2.75
+$0.11 (+4.2%)
Closing price April 23, 2024
Arbutus Biopharma Corp is a biopharmaceutical company focused on developing treatments for chronic Hepatitis B virus (HBV) infection and other coronaviruses, including COVID-19. With a product pipeline that includes a subcutaneously-delivered RNAi therapeutic and an oral HBV RNA destabilizer, Arbutus aims to suppress HBV antigens and reawaken the immune system. The company, which was previously known as Tekmira Pharmaceuticals, collaborates with various pharmaceutical firms and is based in Warminster, Pennsylvania.

As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Jon C. Ogg
Published:

3 COVID-19 Vaccine Trials Are Now in Phase 3, With More on the Way
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Jon C. Ogg
Published:

Moderna's Pain Is Arbutus's Gain in COVID-19 Patent Ruling
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Chris Lange
Published:

Why One Analyst Is Doubling Its Target After Hepatitis B Study
Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with chronic hepatitis B virus infection.
Chris Lange
Published: